In an interview with CancerNetwork®, Henry Adewoye, MD, chief medical officer at Compugen, discussed the study of COM701, which was presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting 2020, held from April 27-28, 2020. COM701 is a novel first-in-class immune checkpoint inhibitor that demonstrated encouraging preliminary antitumor activity with objective responses as a monotherapy and in combination with nivolumab (Opdivo) in hard to treat tumor types, such as primary peritoneal and microsatellite stable colorectal cancer.